EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

R Adelaiye-Ogala, J Budka, NP Damayanti, J Arrington… - Cancer research, 2017 - AACR
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …
被引用次数：76 相关文章

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

R Adelaiye-Ogala, J Budka… - Cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

R Adelaiye-Ogala, J Budka, NP Damayanti… - Cancer …, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Acquired and intrinsic resistance to receptor
tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of …

EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

R Adelaiye-Ogala, J Budka… - Cancer …, 2017 - mdanderson.elsevierpure.com
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …
[PDF] iupui.edu

[PDF][PDF] EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

R Adelaiye-Ogala, J Budka, NP Damayanti, J Arrington… - 2017 - scholarworks.iupui.edu
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represent a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …
[HTML] nih.gov

[HTML][HTML] EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

R Adelaiye-Ogala, J Budka, NP Damayanti… - Cancer …, 2017 - ncbi.nlm.nih.gov
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represent a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

R Adelaiye-Ogala, J Budka, NP Damayanti… - Cancer …, 2017 - europepmc.org
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represent a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …

EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

R Adelaiye-Ogala, J Budka, NP Damayanti… - Cancer …, 2017 - experts.illinois.edu
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

R Adelaiye-Ogala, J Budka, NP Damayanti… - Cancer …, 2017 - europepmc.org
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represent a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …

EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

R Adelaiye-Ogala, J Budka, NP Damayanti, J Arrington… - 2017 - scholarworks.iupui.edu
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represent a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …